Dendritic Cell-based Immunotherapy in Multiple Myeloma

References

• Barlogie, B., Jagannath, S. Desikan, KR., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D. and Crowley, J. (1999) "Total therapy with tandem transplants for newly diagnosed multiple myeloma", Blood 93, 55–65.
   PubMed Web of Science ®Google Scholar
• Desikan, R., Barlogie, B., Sawyer, J.. Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughessy, J., Fassas, A., Lim, S., Roberson, P. and Crowley, J. (2000) "Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities", Blood 95,4008–4010.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Vesole, D.H., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996) "Graft-versus-myeloma effect: proof of principle", Blood 87, 1196–1198.
   PubMed Web of Science ®Google Scholar
• Verdonck, L.F., Lokhorst, H.M„ Dekker, A.W., Nieuwenhuis. H.K. and Petersen, E.J. (1996) "Graft-versus-myeloma effect in two cases", Lancet 347, 800–801.
   PubMed Web of Science ®Google Scholar
• Lynch, R.G., Graff, R.J., Sirisinha, S., Simms, E.S. and Eisen, H.N. (1974) "Myeloma proteins as tumor-specific transplantation antigens", Proc. Nall Acad. Sci. USA 69, 1540–1544.
   Web of Science ®Google Scholar
• Tao, M.H. and Levy, R. (1993) "Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma", Nature 362, 755–758.
   PubMed Web of Science ®Google Scholar
• Sirisinha, S. and Eisen, H.N. (1971) "Autoinunune-like antibodies to the ligand-binding sites of myeloma proteins", Proc. Nat! Acad. Sci. USA 68, 3130–3135.
   PubMed Web of Science ®Google Scholar
• Stevenson, F.K. and Gordon. J. (1983) "Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attach by modulation", J. Immunol. 130, 970–973.
   PubMed Web of Science ®Google Scholar
• Kaminski, M.S Kitamura, K., Maloney, D.G. and Levy, R. (1987) "Idiotype vaccination against murine B cell lymphoma: inhibition of tumor immunity by free idiotype protein", J. Immunol. 138. 1289–1296.
   PubMed Web of Science ®Google Scholar
• Campbell, M.J.,Esserman, L., Byars, N.E., Allison, A.C. and Levy. R. (1990) "Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity", J. IrnmunoL 145, 1029–1036.
   Google Scholar
• Yi, Q., Bergenbrant, S., Osterborg, A., Osby, E., Ostman, R., Bjfirkholm, M., Holm, G. and Lefvert, A.K. (1993) "T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal garrunopathies", Scand. J. Immunol. 38, 529–534.
   PubMed Web of Science ®Google Scholar
• Osterborg, A., Yi, Q., Bergenbrant, S.. Holm, G., Lefvert, A.K. and Mellstedt, H. (1995) "Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests", Br J. Haematol. 89, 110–116.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J., Ling, M. and Lim, S.H. (1998) "Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma", Br J. Haematol. 100, 464–468.
   PubMed Web of Science ®Google Scholar
• Fagerberg, J., Yi, Q., Gigliotti, D., Harrnenberg, U., Ruden, U., Persson, B., Osterborg, A. and Mellstedt, H. (1999) "T cell epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma", Int. .1. Cancer 80, 671–680.
   Web of Science ®Google Scholar
• Yi, Q., Eriksson, I., He, W., Holm, G., Mellstedt, H. and Osterborg, A. (1997) "Idiotype-specific T lymphocytes in monoclonal garrunopathies. Evidence for the presence of CD4+ and CDS+ subsets", Br. J. HaematoL 96, 338–345.
   PubMed Web of Science ®Google Scholar
• Yi, Q., Österborg, A., Bergenbrant, S., Mellstedt, H., Holm, G. and Lefvert, A.K. (1995) "Idiotype-reactive T subsets and tumor load in monoclonal gammopathies", Blood 86, 3043–1049.
   PubMed Web of Science ®Google Scholar
• Walchner, M. and Wick, M. (1997) "Elevation of CD8+ CD1113+ Leu-8- T cells is associated with the humorist immunodeficiency in myeloma patients", Clin. Exp. Immunol, 109, 310–316.
   PubMed Web of Science ®Google Scholar
• Frassani to, M.A., Cusmai, A. and Dammacco, F. (2001) "Deregulated cytokine network and defective Thl in-mune response in multiple myeloma", Clin. Exp. Immunot 125, 190–197.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J., Barlogie, B. and Yi, Q. (2001) "Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells", Blood 97, 1750–1755.
   PubMed Web of Science ®Google Scholar
• Li, Y, Bendandi, M., Deng, Y.. Dunbar, C., Munshi, N., Jagannath, S., Kwak, L.W. and Lyerly, H.K. (2000) "Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells", Blood 96, 2828–2833.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J., Min, R., Tricot, G., Barlogie, B. and Yi, Q. (2002) "Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy", Blood 99, 3280–3285.
   PubMed Web of Science ®Google Scholar
• Dhodapkar,Krasovsky, J. and Olson, K. (2002) "T cells fromthe tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells", Proc. Nat! Acad. Sri. USA 99, 13009–13013.
   PubMed Web of Science ®Google Scholar
• Milazzo, C., Reichardt, V.L., Miller, M.R., Grunebach, F. and Brossart, P. (2003) "Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA", Blood 101, 977–982.
   PubMed Web of Science ®Google Scholar
• van Baren, N., Brasseur, F., Godelaine, 0., Hames, G., Ferrant, A.. Lehmann, F., Andre, M., Ravoet, C., Doyen, C., Spagnoli, G.C., Bakkus, M., Thielemans, K. and Boon, T. (1999) "Genes encoding tumor-specific antigens are expressed in human myeloma cells", Blood 94, 1156–1164.
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck, C., Mellerin. M.P., Labarriere, N., Jego, G., Moreau-Aubry. A.. Harousseau, LL., Jotereau, F. and Bataille, R. (2000) "The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells", Eun Immunol. 30, 803–809.
   PubMed Web of Science ®Google Scholar
• Gupta, S.K., Shaughnessy, J., Droojenbroeck, IV., Szmania, S.M., Zhan, F., Batchu,Spagnoli, G,C., Tricot, G., Pei, L. andvan Rhee, F. (2002) "NY-ES0-1 RNA and protein expression in multiple myeloma is highest in aggressive myeloma and is correlated with chromosomal abnormalities [abstract]". Blood 100, 401a.
   Google Scholar
• Gupta, S.K., Pei, L., Droojenbroeck, J.V., Szmania, S.M.. Yacobby, S., Batchu, R.B., Spagnoli, G.C., Tricot, G., Epstein, J. and van Rhee, F. (2002) "Intra- and intertumoral variation in the expression of cancer testis antigens, MAGE-3 and NY-ESO-1 in multiple myeloma [abstract]", Blood 100, 603a.
   PubMed Web of Science ®Google Scholar
• Szmania, S.M., Bennett. G.. Butchu, R.B., Rosen, N.A., Gupta, S.K. Xie, J., Fox, M., Barlogie, B., Tricot, G., Yi, Q. and van Rhee, F. (2002) "Dendritic cells pulsed with NY-ES0-1 and MAGE-3 peptide stimulate myeloma cytotoxic T lymphocytes [abstract]", Blood 100, 399a.
   Google Scholar
• Treon, S.P., Mollick, LA., Urashinaa, M., Teoh, G., Chauban. D., Ogata, A., Raje, N., Hilgers, J.H., Nadler, L., Belch, A.R., Pilarsld, L.M. and Anderson, K.C. (1999) "Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone", Blood 93, 1287–1298.
   PubMed Web of Science ®Google Scholar
• Lim, S.H., Wang, Z., Chiriva-Intemati, M. and Xue, Y. (2001) "Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma", Blood 97, 1508–1510.
   PubMed Web of Science ®Google Scholar
• Ohtomo, T., Sugamata, Y., Ozaki, Y., Ono, K., Yoshimura, Y, Kawai, S., Koishihara, Y., Ozaki, S., Kosaka, M., Hirano, T. and Tsuchiya, M. (1999) "Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells". Biochem. Biophys. Res. Common. 258, 583–591,
   PubMed Web of Science ®Google Scholar
• Nob, H., Takahashi, T., Makiguchi. Y., Hayashi. T., Hinoda, Y. and Imai, K. (1997) "Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recog-nized an underglycosylated form of MUC I mucin", Int. ',mono'. 9, 791–798.
   Google Scholar
• Chiriva-Internati, M., Wang, Z., Salati, E., Bumm, K., Barlogic, B. and Lim, S.H. (2002) "Sperm protein 17 (Sp17) is a suitable target for inununotherapy of multiple myeloma", Blood 100, 961–965.
   PubMed Web of Science ®Google Scholar
• Lim, S.H., Chiriva-Internati, M., Wang, Z, and Salati, E. (2002) "Sperm protein 17 (Sp17) as a tumor vaccine for multiple myeloma [abstract]", Blood 100, 673a.
   Google Scholar
• Lacy, H.M. and Sanderson, R.D. (2001) "Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion", Blood 98, 2160–2165.
   PubMed Web of Science ®Google Scholar
• Steinman, R.M. and Cohn, Z.A. (1973) "Identification of a novel cell type in peripheral lymphoid organs of mice. 1. Morphology, quantitation, tissue distribution", J. Exp. Med. 137, 1142–1162.
   PubMed Web of Science ®Google Scholar
• Steinman, R.M. (1991) "The dendritic cell system and its role in intinunogenicity", Ann. Rev Monona 9, 271–296.
   Web of Science ®Google Scholar
• Banchereau, J. and Steinman, R.M. (1988) "Dendritic cells and the control of immunity", Nature 392, 245–252.
   Web of Science ®Google Scholar
• Grabbe, S., Beissert, S., Schwartz, T. and Granstein, R.D. (1995) "Dendritic cells as initiators of tumor immune response: a possible strategy for tumor immuuotherapy?", ImmonoL Today 16, 117–121.
   PubMedGoogle Scholar
• Girolomoni, G. and Ricciardi-Castagnoli, P. (1997) "Dendritic cells hold promise for inununotherapy". Immunol. Today 118, 102–104.
   Google Scholar
• Reid, C.D., Stackpoole, A., Meager, A. and Tikerpae, J. (1992) "Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow", J. Iminunol. 149, 2681–2688.
   PubMed Web of Science ®Google Scholar
• Sallusto, F. and Lanzavecchia, A. (1994) "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor a", J. Exp. Med. 179, 1109–1118.
   PubMed Web of Science ®Google Scholar
• Romani, N., Gruner, S., Brang, D., Kampgen. E., Lenz, A„ Trockenbacher, B., Konwalinka, G., Fritsch, P.O., Steinman, A.M. and Schuler, G. (1994) "Proliferating dendritic cell progenitors in human blood", J. Exp. Med, 180, 83–93.
   PubMed Web of Science ®Google Scholar
• Shimizu, J., Suda, T., Yoshioka, T., Kosugi, A., Fujiwara, H. and Hamaoka, T. (1989) "Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells", J. Immunol. 142, 1053–1059.
   PubMed Web of Science ®Google Scholar
• Grabbe, S., Bruvers, S., Gallo, R.L., Knisely, T.L., Nazareno, R. and Granstein, R.D. (1991) "Tumor antigen presentation by murine epidermal cells", J. Immunol. 146, 3656–3661.
   PubMed Web of Science ®Google Scholar
• Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Tielemans, F., Leo, 0., Urbain, J. and Moser M. (1994) "Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo", Ear J. ',mond. 24, 605–610.
   Google Scholar
• Mayordomo, J.1., Loftus, Di., Sakamoto, H., De Casare, C.M., Appasamy, P.M., Lotze, KT., Storkus, W.J., Appella, E. and DeLeo, A.B. (1996) "Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines", J, Exp. Med. 183, 1357–1365,
   PubMed Web of Science ®Google Scholar
• Hsu, EL, Benike, C., Fagnoni, F., Liles, TM., Czerwinski, D., Taidi, B., Engleman. E.G. and Levy. R. (1996) "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells", Nat. Med. 4, 52–58.
   PubMed Web of Science ®Google Scholar
• Nestle, P.O.. Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dimmer. R., Burg, G. and Schadendorf, D. (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells", Nat. Med. 4, 328–332.
   Web of Science ®Google Scholar
• Dabadghao, S,, Bergenbrant, S., Anton, D., He, W., Holm, G. and Yi, Q. (1998) "Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells", Br J. Haematol. 100, 647–654.
   PubMed Web of Science ®Google Scholar
• Butch, A.W., Kelly, K.A. and Munshi, N.C. (2001) "Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein", Exp. Hematol. 29, 85–92.
   PubMed Web of Science ®Google Scholar
• Ratta, M., Curti, A., Fogli, M., Pantucci, M., Visconti, G., Tazzari. P., Fagnoni, F., Vescovini, R., Sansoni, R. Tura, S. and Lemo L.M. (2000) "Efficient presentation of tumor idiotype to autologous T cells by CD83-1- dendritic cells derived from highly purified circulating CDI4+ monocytes in multiple myeloma patients", Exp. Hematol. 28, 931–940.
   Web of Science ®Google Scholar
• Demic, Z., Schenck, K. and Bogen, B. (2000) "Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4-1- T cells", Proc. Nat! Acad. Sci, USA 97, 2697–2702.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J., Ling, M., Bailey-Wood, R. and Lim. S.H. (1998) "Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma", Clin. Cancer Res. 4. 957–962.
   PubMed Web of Science ®Google Scholar
• Lim, S.H. and Bailey-Wood, R. (1999) "Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma", Int. J. Cancer 83, 215–222,
   PubMed Web of Science ®Google Scholar
• Reichardt, V.L., Okada, C.Y., Liso, A., Beike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., Blume. K.G. and Levy, R. (1999) "Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study", Blood 93, 2411–2419.
   PubMed Web of Science ®Google Scholar
• Liso, A., Stockerl-Goldstein, K.E., Auffermann-Gretzinger, S., Beike, C.J., Reichardt, V.L,, van Beckhoven, A., Rajapaksa, R., Engleman, E.G., Blume, K.G. and Levy, R. (2000) "Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma". Biol. Blood Marrow Transplant. 6, 621–627.
   PubMed Web of Science ®Google Scholar
• Cull, G., Durrant, L., Stainer, C., Haynes, A. and Russell, N. (1999) "Generation of anti-idiotype immune responses following vacci-nation with idiotype-protein pulsed dendritic cells in myeloma", Bn I Haematol. 107, 648–655.
   PubMed Web of Science ®Google Scholar
• Titzer, S., Christensen, 0., Manzke, 0,, Tesch, H., Wolf, J., Emmerich, B., Carsten, C., Diehl, V. and Bohlen, H. (2000) "Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects", Br. J. Haematol. 108, 805–816.
   PubMed Web of Science ®Google Scholar
• Lacy, M.Q., Geyer, S., Wettstein, P., Gertz, MA., Gastineau, D.A., Greipp, P.R., Fonseca, R., Dispenzieri, A., Lust, J.A., Witzig, T.E., Rajkumar, S.V., Zeldenrust, S., Maas, M., lturria, N., Weiden, P. and Kyle, R.A. (2002) "Post autologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (dendritic) cells (APC8020) is associated with a trend to longer time to progression [abstract]", Blood 100, 425a.
   Google Scholar
• Eggert, A.A., Schreurs, MW.. Boerman, 0.C., Oyen, W.J., de Boer. AT.. Punt, C.J., Figclor, C.G. and Adema, G.J. (1999) "Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration", Cancer Res. 59, 3340–3345.
   Google Scholar
• Morse, M.A.. Coleman, RE., Akabani, G., Niehaus, N., Coleman, D. and Lyerly, H.K. (1999) "Migration of human dendritic cells after injection in patients with metastatic malignancies", Cancer Res. 59, 56–58.
   PubMed Web of Science ®Google Scholar
• Fong, L., Brockstedt, D., Benike, C., Wu, L. and Engleman, E.G. (2001) "Dendritic cells injected via different routes induce immunity in cancer patients", J. Immunol. 166, 4254–4259.
   PubMed Web of Science ®Google Scholar
• Palucka. K.A., Taquet, N., Sanchez-Chapuis, F. and Gluckman, J.C. (1998) "Dendritic cells as the terminal stage of monocyte differentiation", ./. Immunol. 160, 4587-4595_
   Google Scholar
• Jonuleit, H., Schmitt, E., Schuler, G., Knop, J. and Enk, A.H. (2002) "Induction of interleukin-I0-producing, nonproliferating CD4' T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells", J. Exp. Med. 192, 1213–1222,
   Web of Science ®Google Scholar
• Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Muni, C. and Bhardwaj, N. (2001) "Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells", J. Exp. Med. 193, 233–238.
   PubMed Web of Science ®Google Scholar
• Yi, Q., Desikan, R., Barlogie, B. and Munshi, N. (2002) "Optimising dendritic cell-based immunotherapy in multiple myelotna",J. Haematol. 117, 297–305.
   Web of Science ®Google Scholar
• Szmania, S.M., Rosen, N.A., Gupta, S.K., Batchu, R.B.,Barlogie, B Cottler-Fox, M., Tricot, G., Yi, Q. and van Rhee, F. (2002) "Robust immune responses to vaccination with autologous myeloma tumor lysate loaded dendritic cells [abstract]", Blood 100, 400a.
   Google Scholar
• Gong, J., Chen, D. and Kufe, D. (1997) "Induction of antitumor activity by immunintion with fusions of dendritic and carcinoma cells", NM. Med. 3, 558–561.
   PubMed Web of Science ®Google Scholar
• Wang, J., Saffold. S.. Cao, X., Krauss, J. and Chen, W. (1998) "Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines", J. Immunol. 161, 5516–5524.
   PubMed Web of Science ®Google Scholar
• Gong, J., Chen, D., Kashiwaba, M., Li. Y.. Chen. L., Takeuchi. H., Qu, H., Rowse, G.J., Gendler, S.J. and Kufe, D. (1998) "Reversal of tolerance of human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells", Pnoc. Nat! Acad. Sci. USA 95, 6279–6283.
   Google Scholar
• Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer. U., Ullrich, S., Muller, C.A., Becker, V.. Gross, A.J., Hernmerlein, B., Kanz, L., Muller, G.A. and Ringert, R.H. (2000) "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids", Nat. Med. 6, 332–336.
   PubMed Web of Science ®Google Scholar
• Gong, J., Koido, S., Chen, D., Tanaka, Y, Huang, L., Avigan, D., Anderson, K., Ohno, T. and Kufe, D. (2002) "Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells potentiated by interleukin 12", Blood 99, 2512–2517.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Zhang, W., Chan, T., Saxena, A. and Xiang, J. (2002) "Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity", Leuk. Res. 26, 757–763.
   PubMed Web of Science ®Google Scholar
• Grosman, D.D., Borges, V., Vasir, D., Wu, Z., Anderson, K., Richardson, P., Munshi, N., Kufe, D. and Avigan, D. (2002) "Dendritic cell (DC)-tumor fusions generated with mature as compared to immature DC potently induced myeloma specific immunity [abstract]", Blood 100, 399a.
   Web of Science ®Google Scholar
• Yi, Q. (2002) "Immunoregulatory mechanisms and immuno-therapy", In: Mehta, J. and Singhal. S., eds, Myeloma (Martin Dunitz, London, UK) pp 81–96.
   Google Scholar